CelLBxHealth has announced its strategic decision to discontinue the costs of maintaining its FDA establishment licence and device listing for the Parsortix system. Given Parsortix’s major use in the field currently lies within in-house research and assay development applications (>97%), management does not see the FDA designation as providing any commercial benefit. The device listing may be reinstated, with the payment of applicable annual fees, at a later point in time if deemed to be of comm ....